SGLT2i与恶性肿瘤相关性研究进展

doi:10.19803/j.1672-8629.20250082

摘要/Abstract

摘要： 目的探讨钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）与恶性肿瘤之间的关系,为肿瘤研究提供参考。方法以我国高发癌症类型为目标病种,分析SGLT2i与肺癌、乳腺癌、甲状腺癌、结直肠癌和肝癌相关的最新临床研究和作用机制。结果 SGLT2i可显著降低非小细胞肺癌患者的全因死亡率,显著抑制乳腺癌MCF-7细胞生长,促进甲状腺癌、结直肠癌细胞凋亡,显著降低非酒精性脂肪性肝病和肝癌风险。结论 SGLT2i作为一种潜在抗癌疗法,当前标准化疗方案联合SGLT2i治疗癌症可能成为一种新的研究思路。但在不同癌症类型中的表达和特异性作用机制、不同亚型药物活性及其联合用药疗效和安全性尚需更多实验证据。

关键词: 钠-葡萄糖共转运蛋白2抑制剂, 肺癌, 乳腺癌, 甲状腺癌, 结直肠癌, 肝癌, 恶性肿瘤, 机制

Abstract: Objective To explore the correlations between SGLT2i as a new anti-tumor drug for regulating glucose uptake and malignant tumors in order to provide data for tumor research. Methods The latest research findings on the mechanism of SGLT2i in lung cancer, breast cancer, thyroid cancer, colorectal cancer and liver cancer were reviewed. Results SGLT2i could significantly reduce the all-cause mortality of NSCLC patients, effectively inhibit the growth of MCF-7 cells of breast cancer, promote apoptosis of thyroid cancer and colorectal cancer cells, and drastically reduce the risk of non-alcoholic fatty liver disease and liver cancer. Conclusion The combination of SGLT2i as a potential anti-cancer therapy with current standard chemotherapy may offer a new line of thought for research. However, the expressions and specific mechanism of action of SGLT2i in different cancers, the activity of drugs of different subtypes and the efficacy and safety of the combination of drugs require more experimental evidence.

Key words: SGLT2i, Lung Cancer, Breast Cancer, Thyroid Cancer, Colorectal Cancer, Liver Cancer, Malignant Tumor, Mechanism

中图分类号:

R979.1

高彩云, 王博媛, 高晓洁. SGLT2i与恶性肿瘤相关性研究进展[J]. 中国药物警戒, 2025, 22(7): 836-840.

GAO Caiyun, WANG Boyuan, GAO Xiaojie. Research Progress in Correlations between SGLT2 Inhibitors and Malignant Tumors[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 836-840.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250082

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I7/836

参考文献

[1] LI BJ, CHANG X, WANG K.Analysis of the Effect of SGLT2i Combined with ARB on Blood Pressure in Elderly Patients with Isolated Systolic Hypertension Complicated with Type 2 Diabetes Mellitus[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine(中国循证心血管医学杂志), 2023, 15(9): 1092-1095.
[2] BU XH.Research Progress on the Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Tumors[J]. Drugs & Clinic(现代药物与临床), 2021, 36(8): 1756-1760.
[3] National Center for Gerontology, Geriatrics Society of Chinese Medical Association, Diabetes Professional Committee of Chinese Geriatric Health Care Association. Guidelines for the Diagnosis and Treatment of Diabetes in the Elderly in China (2024 edition)[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2024, 15(4): 771-800.
[4] KALRA S, SHETTY KK, NAGARAJAN VB, et al.Basic and Clinical Pharmaco Therapeutics of SGLT2 Inhibitors: a Contemporary Update[J]. Diabetes Therapy, 2020, 11(4): 813-833.
[5] GONG C, SHEN SC, ZHANG K, et al.Association of Sodium-Glucose Cotransporter 2 Inhibitors with Cardiovascular Outcome and Safety Events: a Meta-Analysis of Randomized Controlled Clinical Trials[J]. Frontiers in Cardiovascular Medicine, 2022, 9: 926979.
[6] SIDDIQUI RK, OBI Y, DOSSABHOY NR, et al.Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?[J]. Current Hypertension Reports, 2024, 26(12): 463-474.
[7] HAN T, FAN Y, GAO J, et al.Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin Depressed Adiposity and Ameliorated Hepatic Steatosis in High-Fat Diet Induced Obese Mice[J]. Adipocyte, 2021, 10(1): 446-455.
[8] WEI HY, GUO YJ.Systematic Review of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Non-Diabetic Diseases[J]. Medical Information(医学信息), 2024, 37(16): 173-177.
[9] BIE BK, ZHANG Y.Analysis of the Impact of Sodium-Glucose Cotran-sporter 2 Inhibitors on the Prognosis of Heart Failure Patients in the Real World[J]. Chinese Journal of Cardiovascular Research(中国心血管病研究), 2024, 22(11): 1013-1020.
[10] YE YJ, GU JF.Role and Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors in Obesity-Related Nephropathy[J]. Chinese Journal of Clinical Healthcare(中国临床保健杂志), 2024, 27(5): 705-710.
[11] SUN LJ, JIANG GR.Progress and Prospects of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2024, 44(9): 783-788.
[12] BASAK D, GAMEZ D, DEB S.SGLT2 Inhibitors as Potential Anticancer Agents[J]. Biomedicines, 2023, 11(7): 1867.
[13] TENG Y, ZHANG XD, XIA CF, et al.Comparison and Prediction Analysis of Cancer Incidence, Mortality and Morbidity between China and the World: Interpretation of GLOBOCAN 2022 Data[J]. Chinese Journal of Cancer Prevention and Treatment(中华肿瘤防治杂志), 2024, 31(23): 1413-1420.
[14] SHEN XL, ZHAO LZ, DENG R, et al.Research Progress of STING Agonists and Tumors[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2024, 29(4): 305-309.
[15] SCAFOGLIO CR, VILLEGAS B, ABDELHADY G, et al. Sodium-Glucose Transporter 2 Is a Diagnostic and Therapeutic Target for Early-Stage Lung Adenocarcinoma[J]. Science Translational Medicine, 2018, 10(467): eaat5933.
[16] SUN M, SUN J, SUN W, et al.Unveiling the Anticancer Effects of SGLT2i: Mechanisms and Therapeutic Potential[J]. Frontiers in Pharmacology, 2024, 15: 1369352.
[17] YAMAMOTO L, YAMASHITA S, NOMIYAMA T, et al.Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Attenuates Lung Cancer Cell Proliferation in vitro[J]. Diabetology International, 2021, 12, 389-398.
[18] LUO J, HENDRYX M, DONG Y.Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Non-Small Cell Lung Cancer Survival[J]. British Journal of Cancer, 2023, 128(8): 1541-1547.
[19] SHAPIRO SB, YIN H, YU OHY, et al.Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Lung Cancer among Patients with Type 2 Diabetes[J]. British Journal of Clinical Pharmacology, 2024, 90(5): 1365-1370.
[20] LAU KTK, NG L, WONG JWH, et al.Repurposing Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) for Cancer Treatment-a Review[J]. Reviews in Endocrine & Metabolic Disorders, 2021, 22(4): 1121-1136.
[21] WU W, ZHANG Z, JING D, et al.SGLT2 Inhibitor Activates the STING/IRF3/IFN-β Pathway and Induces Immune Infiltration in Osteosarcoma[J]. Cell Death and Disease, 2022, 13(1): 523.
[22] CHANG A, BOTTERI E, GILLIS RD, et al. Beta-Blockade Enhances Anthracycline Control of Metastasis in Triple-Negative Breast Cancer[J]. Science Translational Medicine, 2023, 15(693): eadf1147.
[23] PAPADOPOLI D, UCHENUNU O, PALIA R, et al.Perturbations of Cancer Cell Metabolism by the Antidiabetic Drug Canagliflozin[J]. Neoplasia, 2021, 23(4): 391-399.
[24] ZHOU J, ZHU J, YU SJ, et al.Sodium-Glucose Co-Transporter-2(SGLT-2) Inhibition Reduces Glucose Uptake to Induce Breast Cancer Cell Growth Arrest through AMPK/mTOR Pathway[J]. Biomedicine & Pharmacotherapy, 2020, 132: 110821.
[25] KOMATSU S, NOMIYAMA T, NUMATA T, et al.SGLT2 Inhibitor Ipragliflozin Attenuates Breast Cancer Cell Proliferation[J]. Endocrine Journal, 2020, 67(1): 99-106.
[26] CHEN J, LIU YB, MAO M, et al.Research on the Cardiovascular Protective Effect of Sodium-Glucose Co-Transporter 2 Inhibitors in Breast Cancer Patients Undergoing Chemotherapy[J]. Journal of Modern Medicine & Health(现代医药卫生), 2023, 39(24): 4167-4171.
[27] BEA S, SON H, BAE JH, et al.Risk of Thyroid Cancer Associated with Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: a Population-Based Cohort Study[J]. Diabetes, Obesity and Metabolism, 2024, 26(1): 108-117.
[28] PASTERNAK B, WINTZELL V, HVIID A, et al.Glucagon-Like Peptide 1 Receptor Agonist Use and Risk of Thyroid Cancer: Scandinavian Cohort Study[J]. British Medical Journal, 2024, 385: e078225.
[29] WANG Y, YANG L, MAO L, et al.SGLT2 Inhibition Restrains Thyroid Cancer Growth via G1/S Phase Transition Arrest and Apoptosis Mediated by DNA Damage Response Signaling Pathways[J]. Cancer Cell International, 2022, 22(1): 74.
[30] CHIANG CH, CHIANG CH, HSIA YP, et al.The Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Outcome of Patients with Diabetes Mellitus and Colorectal Cancer[J]. Journal of Gastroenterology and Hepatology, 2024, 39(5): 902-907.
[31] ANASTASIO C, DONISI I, DEL VECCHIO V, et al.SGLT2 Inhibitor Promotes Mitochondrial Dysfunction and ER-Phagy in Colorectal Cancer Cells[J]. Cell & Molecular Biology Letters, 2024, 29(1): 80.
[32] ABDEL-RAFEI MK, THABET NM, RASHED LA, et al.Canagliflozin, a SGLT-2 Inhibitor, Relieves ER Stress, Modulates Autophagy and Induces Apoptosis in Irradiated HepG2 cells: Signal Transduction between PI3K/AKT/GSK-3β/mTOR and Wnt/β-Catenin Pathways; in vitro[J]. Journal of Cancer Research and Therapeutics, 2021, 17(6): 1404-1418.
[33] NAKANO D, KAWAGUCHI T, IWAMOTO H, et al.Effects of Canagliflozin on Growth and Metabolic Reprograming in Hepatocellular Carcinoma Cells: Multi-Omics Analysis of Metabolomics and Absolute Quantification Proteomics (iMPAQT)[J]. PLoS One, 2020, 15(4): e0232283.
[34] LUO J, SUN P, ZHANG X, et al.Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway[J]. International Journal of Molecular Sciences, 2021, 22(24): 13336.
[35] LI L, LI Q, HUANG W, et al.Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway[J]. Frontiers in Pharmacology, 2021, 12: 589273.
[36] CHO HJ, LEE E, KIM SS, et al.SGLT2i Impact on HCC Incidence in Patients with Fatty Liver Disease and Diabetes: a Nation-Wide Cohort Study in South Korea[J]. Scientific Reports, 2024, 14(1): 9761.
[37] OSCAR H, JING N, RAYMOND N, et al. Lower Risks of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Compared to Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma in Type 2 Diabetes Mellitus: a Population-Based Study[EB/OL]. [2025-06-04]. https://doi.org/ 10.1101/2022.08.16.22278847.
[38] MURAKAMI K, SASAKI Y, ASAHIYAMA M, et al.Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis[J]. Cells, 2022, 11(4): 720 .
[39] YOSHIOKA N, TANAKA M, OCHI K, et al.The Sodium-Glucose Cotransporter-2 Inhibitor Tofogliflozin Prevents the Progression of Nonalcoholic Steatohepatitis-Associated Liver Tumors in a Novel Murine Model[J]. Biomedicine & Pharmacotherapy, 2021, 140: 111738.
[40] BASAK D, GAMEZ D, DEB S.SGLT2 Inhibitors as Potential Anticancer Agents[J]. Biomedicines, 2023, 11(7): 1867.
[41] WANG XJ, ZHAO WH, XIAO JZ.Sodium-Glucose Cotransporter 2 Inhibitors in Post-Transplant Diabetes Mellitus[J]. Chinese Journal of Diabetes(中华糖尿病杂志), 2023, 15(7): 661-664.
[42] KOGOT LA, RIAHI Y, ABRAMOVICH I, et al.Mapping the Metabolic Reprogramming Induced by Sodium-Glucose Cotransporter 2 Inhibition[J]. Journal of Clinical and Investigative Insight, 2023, 8(7): e164296.
[43] LIU W, YOU D, LIN J, et al.SGLT2 Inhibitor Promotes Ketogenesis to Improve MASH by Suppressing CD8+ T Cell Activation[J]. Cell Metabolism, 2024, 36(10): 2245-2261.
[44] YOKOSE C, MCCCORMICK N, ABHISHEK A, et al.The Clinical Benefits of Sodium-Glucose Cotransporter Type 2 Inhibitors in People with Gout[J]. Nature Reviews Rheumatology, 2024, 20(4): 216-231.
[45] ZHENG J, LU J, QI J, et al.The Effect of SGLT2 Inhibition on Prostate Cancer: Mendelian Randomization and Observational Analysis Using Electronic Healthcare and Cohort Data[J]. Cell Reports Medicine, 2024, 5(8): 101688.
[46] Canada Releases new Safety Information on the Risk of Diabetic Ketoacidosis Associated with Sodium-Glucose Co-Transporter 2 Inhibitors[J]. Chinese Journal of Drug Evaluation(中国药物评价), 2024, 41(5): 361.
[47] ZHANG RX, ZHAO J, MOU LN.Meta-Analysis of Ketoacidosis Caused by Sodium-Glucose Co-Transporter 2 Inhibitors and Nursing Countermeasures[J]. Chinese Journal of Nursing(中华护理杂志)2024, 59(3): 353-362.
[48] HUNG MH, CHEN YL, CHEN LJ, et al.Canagliflozin Inhibits Growth of Hepatocellular Carcinoma via Blocking Glucose-Influx-Induced β-Catenin Activation[J]. Cell Death & Disease, 2019, 10(6): 420.
[49] ZHENG GM, XIE ZY, CHENG XL, et al. One Case of Euglycemic Diabetic Ketoacidosis Caused by Metformin Hydrochloride and Empag-liflozin Tablets[J/OL]. Chinese Journal of Pharmacovigilance(中国药物警戒), (2025-05-30)[2025-06-04]. https://doi.org/10.19803/j.1672-8629.20240845.